

University of Toledo  
Institutional Biosafety Committee

**Date:** November 20, 2025

**Meeting time:** 12.00 pm- 2.00 pm

**Meeting type:** Hybrid (Microsoft Teams and HEB 233)

**Attendees/Roster:**

| <b>Member</b>                  | <b>Attended</b> | <b>Voting</b> | <b>Scientific</b> | <b>Affiliated</b> |
|--------------------------------|-----------------|---------------|-------------------|-------------------|
| DeLaSerna, Ivana               | Yes             | Yes           | Yes               | Yes               |
| Dinardo, Robert S              | No              | Yes           | Yes               | No                |
| Dudley, Richard                | Yes             | Yes           | Yes               | No                |
| Gray, John                     | Yes             | Yes           | Yes               | Yes               |
| Kalinoski, Andrea L.           | Yes             | Yes           | Yes               | Yes               |
| Leisner, Scott M.              | Yes             | Yes           | Yes               | Yes               |
| Peseckis, Steven M.            | Yes             | Yes           | Yes               | Yes               |
| Pillai, Mahesh R               | Yes             | Yes           | Yes               | Yes               |
| Rohrs, Skylar Lee              | Yes             | Yes           | Yes               | Yes               |
| Root, Lisa Jane                | Yes             | Yes           | Yes               | Yes               |
| Shemshedini, Lirim             | Yes             | Yes           | Yes               | Yes               |
| Shupp, Andrew<br>Charles (Alt) | Yes             | No            | Yes               | Yes               |
| Taylor, Roger Travis           | Yes             | Yes           | Yes               | Yes               |
| Wooten, Ronald<br>Mark         | Yes             | Yes           | Yes               | Yes               |
|                                |                 |               |                   |                   |
|                                |                 |               |                   |                   |
|                                |                 |               |                   |                   |
|                                |                 |               |                   |                   |
| Guests: [REDACTED]             |                 |               |                   |                   |
| IBC staff: Lederer, Nicole     |                 |               |                   |                   |

**Quorum:** Present

*There were (11) voting members present, and (7) members are required to conduct business.*

**Call to Order:** The IBC Chair called the meeting to order at 12.08 pm

Dr. Peseckis introduced his guest, Jessica Pham, a PharmD student shadowing him.

**Review and approval of previous minutes:**

Meeting minutes were shared, Dr. Wooten mentioned that July’s were previously approved but modified per the PI’s request prior to being posted. Dr. Wooten opened the floor for any member questions/concerns with July and August minutes.

**Date of the meeting minutes to be approved. July 10, 2025**

- **Discussion:** None
- **Motion:** The committee approved the unredacted updated July meeting minutes as written.
- **Votes:** For/Against/Abstain: 11/0/0

- **Date of the meeting minutes to be approved.** August 21, 2025
- **Discussion:** None.
- **Motion:** The committee approved the unredacted August meeting minutes as written.
- **Votes:** For/Against/Abstain: 11/0/0

**Review of Prior Business/Biosafety officers report:**

- Mr. Rohrs mentioned [REDACTED]  
[REDACTED] CDC inspection is expected in March. EPA will start inspecting again, this is expected to be sometime in March or April.

**Protocol Review**

*[Dr. Kalinoski joined the meeting at 12.13 PM, total voting members 12, quorum was maintained]*

|   |                              |  |  |
|---|------------------------------|--|--|
| <b>IBC</b><br>#500178-<br>New<br>Submission   | <b>P.I.:</b> Dr.Anan Bseiso. | <b>Training:</b> IBC Laboratory<br>Safety Training | <b>Biosafety Level<br/>Assignment:</b> BSL-2 |
| <b>Title:</b> Hormonal Receptor Expression in Papillary Thyroid Carcinoma: Understanding Its Impact on Prevalence and Aggressiveness in Pre- and Postmenopausal Women |                              |  |  |

Project Overview:

The purpose of this research is to investigate the role of hormonal receptor expression (estrogen and progesterone receptors) in the development and aggressiveness of papillary thyroid carcinoma (PTC) in pre- and postmenopausal women. The objective is to assess how hormonal influences, reflected in receptor expression, contribute to the higher prevalence of PTC in females and its potential impact on tumor characteristics and aggressiveness.

NIH Guideline Section

Not applicable. Recombinant and Synthetic DNA are not involved

Risk Assessment and Discussion

Types of biological hazards associated with this protocol are as follows,

- Surgically resected thyroid tissue samples from human patients
- Chemical reagents such as formalin (used for tissue fixation), xylene (used for deparaffinization), ethanol, and various buffers used in immunohistochemical staining
- Cell lines

Potential sources of risk are through aerosols, needle sticks, and chemical hazards. The committee discussed the proposed precautions outlined in the protocol such as PPE requirements, handling of aerosol generating equipment, safe handling and disposal of sharps and determined that the proposed precautions are appropriate and sufficient.

Occupational Health Representative review (if applicable):

- All potentially infectious material work must be done in a Biosafety cabinet
- Safety needles and safety scalpels should be used.
- SOP states that "N95 masks or face shields will be worn when there is a potential for aerosol generation." All aerosol generating activities should be done inside a biosafety cabinet. If they can not, then N95s can be worn, but only after approval through EHRS including a fit test and medical clearance.

IBC vote:

A member made a motion for Modifications required for approval, then Designated Member Review (Chair only). Another member seconded. The required modifications were:

1. All the comments from the biosafety officer (listed above).

Total Votes: 12, For: 12, Against: 0, Abstain: 0

|   |  |  |   |
|---|--|--|---|
| <b>IBC #500188-</b><br>New<br>Submission  | <b>P.I.:</b> Dr. Frederick<br>Williams | <b>Training:</b> IBC Biosafety<br>Training and IBC<br>Laboratory Safety Training | <b>Biosafety<br/>Level<br/>Assignment:</b><br>BSL-2 |
| <b>Title:</b> Evaluating Inducible Nitric Oxide Synthase, Nitrosative Stress, and Oxidative Stress Regulation Using In Vitro Models   |  |  |   |
| <p><u>Project Overview:</u></p> <p>A major driver of neuronal and glial injury in multiple sclerosis (MS) is oxidative and nitrosative stress, largely mediated by inducible nitric oxide synthase (iNOS). Research suggests a feedback loop in which nitric oxide (NO) can suppress iNOS expression in a concentration-dependent manner. This project will establish and validate an iNOS–NO feedback model by testing sodium nitroprusside and other nitric oxide donor compounds in both macrophage and neuroblastoma models. The objectives are to define non-toxic, NO-equivalent dosing ranges between compounds and determine whether NO release suppresses iNOS expression and reduces nitrosative/oxidative stress.</p>  |  |  |   |
| <p><u>NIH Guideline Section</u></p> <p>Not applicable. Recombinant and Synthetic DNA are not involved</p>   |  |  |   |
| <p><u>Risk Assessment and Discussion</u></p> <p>Types of biological hazards associated with this protocol are as follows,</p> <ul style="list-style-type: none"> <li>• Cell lines - RAW 264.7 cells and SH-SY5Y cells</li> <li>• Chemical hazards - lipopolysaccharide, interferon-gamma, sodium nitroprusside, furoxans, and other standard laboratory chemical hazards.</li> </ul> <p>Potential sources of risk include exposure to cell culture reagents, furoxans, lipopolysaccharide, and Human Interferon gamma. Risks to personnel include accidental skin or eye contact with chemicals. There is minimal risk to the environment, as all biological and chemical waste will be disposed of according to institutional biosafety procedures. The committee discussed the proposed precautions outlined in the protocol such as PPE requirements, waste disposal procedures, appropriate use and handling of tissue samples and determined that the proposed precautions are appropriate and sufficient.</p> |  |  |   |
| <p><u>Occupational Health Representative review (if applicable):</u></p> <ul style="list-style-type: none"> <li>• Lab spaces need to be inspected as BSL2. PI to contact the biosafety officer to schedule inspection.</li> </ul>   |  |  |   |
| <p><u>IBC vote:</u></p> <p>A member made a motion for ‘Modifications required for approval, then Designated Member Review (Chair only). Another member seconded. The required modifications were:</p>   |  |  |   |

1. Please cite Appendix H of the BMBL and list possible blood borne pathogens that can come from the SH-SY5Y neuroblastoma human cells.

Total Votes: 12, For: 12, Against: 0, Abstain: 0

**New Business/Additional Topics:** none

**Review of incidents:** none

**Inspections/Ongoing oversight:** none

**IBC training for members:** none

**Public comments:** none

**Adjournment:** The IBC Chair moved to adjourn the meeting at 12.40 PM. The next meeting scheduled is for December 18<sup>th</sup> at 12.00 PM via MS Teams and in-person (HEB 233).